Research programme: neurobehavioural disorders therapeutics - BlackThorn Therapeutics
Latest Information Update: 26 Oct 2016
At a glance
- Originator BlackThorn Therapeutics
- Class Small molecules
- Mechanism of Action Opioid kappa receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 20 Oct 2016 Preclinical trials in Neurological disorders in USA (unspecified route) (BlackThorn Therapeutics pipeline, October 2016)